Literature DB >> 7562248

Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers.

L G Bobrow1, L C Happerfield, W M Gregory, R R Millis.   

Abstract

One hundred and five cases of pure ductal carcinoma in situ (DCIS) seen in the Guy's Hospital breast unit between 1975 and 1991 were reviewed. The presence and extent of necrosis and the degree of cytonuclear differentiation were assessed and the expression of p53 protein, cerbB2 protein, progesterone receptor, and a proliferation antigen KiS1, all factors reported to be of prognostic significance in invasive ductal carcinoma, was evaluated using immunohistochemical methods. A strong correlation was seen between the presence and extent of necrosis and the degree of cytonuclear differentiation and between both these morphological criteria and the biological markers as well as between the individual markers. The presence of extensive necrosis was associated with lack of cytonuclear differentiation and both were associated with a high proliferation rate, the presence of cerbB2 and p53 protein, and the absence of progesterone receptors. In cases with little or no necrosis, there was good nuclear differentiation and a strong correlation with the presence of progesterone receptor, absence of cerbB2 and p53 protein, and a low rate of proliferation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562248     DOI: 10.1002/path.1711760404

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.

Authors:  A J Rice; M A Steward; C M Quinn
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Authors:  Kalliopi P Siziopikou; Stewart J Anderson; Melody A Cobleigh; Thomas B Julian; Douglas W Arthur; Ping Zheng; Eleftherios P Mamounas; Eduardo R Pajon; Robert J Behrens; Janice F Eakle; Nick C Leasure; James N Atkins; Jonathan A Polikoff; Thomas E Seay; Worta J McCaskill-Stevens; Rachel Rabinovitch; Joseph P Costantino; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2013-11-08       Impact factor: 4.872

3.  Cytological and architectural heterogeneity in ductal carcinoma in situ of the breast.

Authors:  C M Quinn; J L Ostrowski
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

4.  C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast.

Authors:  Filiz Eren; Zerrin Calay; Haydar Durak; Bülent Eren; Nil Comunoğlu; Ovgü Aydin
Journal:  Bosn J Basic Med Sci       Date:  2012-02       Impact factor: 3.363

5.  Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors.

Authors:  A G A Selim; G El-Ayat; C A Wells
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

6.  p53 mutations and expression in breast carcinoma in situ.

Authors:  J Lukas; N Niu; M F Press
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 7.  P53, apoptosis, and breast cancer.

Authors:  D M Barnes; R S Camplejohn
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

8.  Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ.

Authors:  K E Munn; R A Walker; L Menasce; J M Varley
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

9.  Molecular grading of ductal carcinoma in situ of the breast.

Authors:  Rosemary L Balleine; Lucy R Webster; Sean Davis; Elizabeth L Salisbury; Juan P Palazzo; Gordon F Schwartz; Dennis B Cornfield; Robert L Walker; Karen Byth; Christine L Clarke; Paul S Meltzer
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 13.801

10.  COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.

Authors:  G P Boland; I S Butt; R Prasad; W F Knox; N J Bundred
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.